Concepedia

Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer

Lauren Dockery, Abby R. Rubenstein, Kai Ding, S.G. Mashburn, Wesley C. Burkett, Allison M. Davis, David W. Doo, Rebecca C. Arend, Kathleen N. Moore, Camille C. Gunderson

Gynecologic Oncology · 2019 · 19 citations · 16 references

DOI

Concepts

References

16

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text

, , +17

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Carol Aghajanian, Stephanie V. Blank, Barbara A. Goff et al. · Journal of Clinical Oncology · 2012 · 1.4K citations · Full text

, , +16

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial

Mahesh Parmar, Jonathan A. Ledermann, Nicoletta Colombo et al. · The Lancet · 2003 · 1.2K citations

, , +17

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.

Maurie Markman, Robert Rothman, Thomas B. Hakes et al. · Journal of Clinical Oncology · 1991 · 854 citations

, , +13

Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG

Jacobus Pfisterer, Marie Plante, Ignace Vergote et al. · Journal of Clinical Oncology · 2006 · 751 citations · Full text

, , +17